Who Owns Nuvaxovid?
Nuvaxovid (NVX-CoV2705) is owned by Novavax, Inc. (Nasdaq: NVAX), a publicly traded American biotechnology company headquartered in Gaithersburg, Maryland. The FDA granted emergency use authorization for the Novavax COVID-19 Vaccine, Adjuvanted on July 13, 2022, and approved a biologics license application (BLA) for Nuvaxovid on May 19, 2025. Nuvaxovid is a protein-based recombinant nanoparticle vaccine using Novavax's proprietary Matrix-M adjuvant, providing a non-mRNA alternative to the Pfizer-BioNTech and Moderna COVID-19 vaccines. Nuvaxovid is not a Merck product.
Parent Company
Novavax, Inc.
Founded
2022
Status
Publicly Traded
Headquarters
Gaithersburg, Maryland, USA
Who Owns Nuvaxovid?
- Parent Company: Novavax, Inc.
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: Nasdaq: NVAX
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Nuvaxovid | Novavax, Inc. | Wholly owned |
History of Nuvaxovid
- Founded: 2022
- Founders: Novavax, Inc. (developer)
Nuvaxovid's development originated from Novavax's decades of experience developing protein-based vaccines using recombinant nanoparticle technology. Novavax was founded in 1987 and spent years developing vaccine candidates for influenza, respiratory syncytial virus (RSV), and other infectious diseases before the COVID-19 pandemic created an urgent need for new vaccine technologies.
Novavax's vaccine platform is based on two core technologies. The first is recombinant nanoparticle technology, in which the target antigen (in Nuvaxovid's case, the SARS-CoV-2 spike protein) is expressed in insect cells using a baculovirus expression system and then assembled into nanoparticles that mimic the structure of the virus. The second is the Matrix-M adjuvant, a saponin-based adjuvant derived from the bark of the Quillaja saponaria tree that enhances the immune response to the vaccine antigen by activating antigen-presenting cells and promoting both cellular and humoral immunity.
When SARS-CoV-2 emerged in late 2019 and the COVID-19 pandemic was declared in March 2020, Novavax rapidly applied its recombinant nanoparticle platform to develop a COVID-19 vaccine candidate designated NVX-CoV2373. The company received funding from the US government's Operation Warp Speed program and from the Coalition for Epidemic Preparedness Innovations (CEPI) to support the development and manufacture of its COVID-19 vaccine.
Novavax conducted the PREVENT-19 Phase 3 clinical trial in the United States and Mexico, which enrolled approximately 30,000 adults. The trial demonstrated that NVX-CoV2373 was 90.4 percent effective against symptomatic COVID-19 and 100 percent effective against moderate and severe disease, with a favorable safety profile. The vaccine was also evaluated in a Phase 3 trial in the United Kingdom, which showed 89.7 percent efficacy.
The FDA granted emergency use authorization for the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) on July 13, 2022, for individuals 18 years and older, making it the fourth COVID-19 vaccine authorized in the United States after the Pfizer-BioNTech, Moderna, and Johnson and Johnson vaccines. The authorization was later extended to adolescents aged 12 to 17 years.
Nuvaxovid's protein-based mechanism differentiates it from the mRNA-based Pfizer-BioNTech and Moderna vaccines and the viral vector-based Johnson and Johnson vaccine. As a traditional protein subunit vaccine, Nuvaxovid uses an established vaccine technology platform that has been used for decades in vaccines such as the hepatitis B vaccine and the human papillomavirus (HPV) vaccine. This traditional technology may be preferred by individuals who are hesitant about mRNA vaccine technology or who have had adverse reactions to mRNA vaccines.
Novavax updated Nuvaxovid's formulation to target emerging SARS-CoV-2 variants, including the XBB.1.5 variant (2023-2024 formula) and the JN.1 variant (2024-2025 formula). The FDA approved a biologics license application (BLA) for Nuvaxovid (NVX-CoV2705, the JN.1-targeting formulation) on May 19, 2025, converting the vaccine from emergency use authorization to full FDA approval for individuals 12 years and older.
In May 2023, Novavax and Sanofi entered into a co-commercialization and licensing agreement under which Sanofi paid approximately $1.2 billion upfront and agreed to co-commercialize Nuvaxovid globally. Sanofi took responsibility for commercializing Nuvaxovid in most markets outside the United States, leveraging its global vaccine commercial infrastructure to expand Nuvaxovid's reach.
About Novavax, Inc.
American biotechnology company founded in 1987, known for vaccine development including the NVX-CoV2373 COVID-19 vaccine, headquartered in Gaithersburg, Maryland.
- Founded: 1987
- Headquarters: Gaithersburg, Maryland, USA
- Company Type: Publicly Traded
- Stock: Nasdaq: NVAX
- Revenue: approximately $1.2 billion (FY2024)
- Employees: approximately 2,000
Where Is Nuvaxovid Made / Based?
- Headquarters: Gaithersburg, Maryland, USA
- Manufacturing / Operations: United States, Czech Republic, South Korea
Nuvaxovid Sustainability & Ethics
Novavax operates under a comprehensive Environmental, Social, and Governance (ESG) framework focused on four strategic pillars: improving global health, ensuring access to vaccines, maintaining high governance standards, and mitigating environmental impact. The company's sustainability approach is integrated into its business operations and corporate strategy.
Environmental Commitment: Novavax aims to operate in an environmentally sustainable manner that reduces its environmental impact across its manufacturing and research operations. The company focuses on responsible resource management, waste reduction, and energy efficiency in its biomanufacturing facilities. Novavax's environmental initiatives include optimizing manufacturing processes to reduce water and energy consumption, implementing sustainable waste management practices, and evaluating the environmental footprint of its supply chain operations.
Global Health Access: A core component of Novavax's sustainability strategy is maximizing access to vaccines and improving global health outcomes. The company works to ensure equitable access to Nuvaxovid through partnerships with global health organizations, tiered pricing for different markets, and technology transfer agreements with international manufacturers. Novavax's partnership with Sanofi significantly expands global access to Nuvaxovid, particularly in low and middle-income countries where vaccine access has historically been limited.
Ethical Research and Development: Novavax maintains high ethical standards in its clinical research and development programs. The company conducts rigorous clinical trials following Good Clinical Practice guidelines, ensures informed consent from trial participants, and maintains transparency in reporting clinical trial results. Novavax's protein subunit technology platform is developed with attention to safety, efficacy, and ethical considerations in vaccine development.
Governance and Compliance: Novavax operates under strong corporate governance principles with oversight from an independent Board of Directors. The company maintains compliance with regulatory requirements across all markets where Nuvaxovid is sold, including FDA regulations, European Medicines Agency standards, and other international regulatory frameworks. Novavax's governance structure includes risk management, compliance programs, and ethical business practices appropriate for a publicly traded biotechnology company.
Awards & Recognition
Nuvaxovid and Novavax have received recognition primarily for scientific innovation and regulatory achievements rather than traditional corporate awards. The vaccine's development and approval represent significant scientific achievements in protein subunit vaccine technology.
Regulatory Milestones: The FDA approval of Nuvaxovid's biologics license application on May 19, 2025, marked a significant regulatory achievement, making Nuvaxovid the first protein subunit COVID-19 vaccine to receive full FDA approval. This regulatory milestone distinguishes Nuvaxovid from other COVID-19 vaccines that remain under emergency use authorization.
Scientific Recognition: Novavax's recombinant nanoparticle technology and Matrix-M adjuvant platform have been recognized for their innovation in vaccine development. The 90.4 percent efficacy demonstrated in the PREVENT-19 Phase 3 trial established the scientific validity of protein subunit vaccines for COVID-19, contributing to the broader scientific understanding of vaccine technologies.
Industry Recognition: Novavax has been recognized within the biotechnology and pharmaceutical industry for its rapid development of a COVID-19 vaccine using an innovative platform. The company's ability to develop, manufacture, and seek regulatory approval for Nuvaxovid demonstrated the potential of smaller biotechnology companies to compete in the global vaccine market.
Partnership Achievement: The 2023 co-commercialization agreement with Sanofi, valued at approximately $1.2 billion upfront plus ongoing royalties, represents industry recognition of Nuvaxovid's commercial potential and Novavax's technological capabilities. This partnership is one of the significant deals in the COVID-19 vaccine sector.
Nuvaxovid Recalls & Controversies
Nuvaxovid has maintained a relatively favorable safety profile compared to some controversies that have affected other COVID-19 vaccines, though the vaccine has faced some challenges related to market adoption and regulatory processes.
Regulatory Authorization Delays: Novavax experienced delays in obtaining regulatory authorization for Nuvaxovid compared to mRNA vaccine manufacturers. The FDA granted emergency use authorization later than initially anticipated, in July 2022, which limited Nuvaxovid's market share during the peak COVID-19 vaccination period. These delays were primarily due to manufacturing facility inspections and data review processes rather than safety concerns.
Manufacturing Challenges: Novavax faced manufacturing challenges early in Nuvaxovid's development, including issues with scaling up production of the recombinant nanoparticle antigen and Matrix-M adjuvant. These challenges contributed to delays in meeting supply commitments and limited the vaccine's availability in some markets during the initial rollout period.
Myocarditis and Pericarditis Risk: Like other COVID-19 vaccines, Nuvaxovid carries a identified risk of myocarditis and pericarditis, particularly in young male recipients. The FDA labeling includes warnings about these risks, and the Centers for Disease Control and Prevention has published clinical considerations for vaccination of individuals with a history of myocarditis or pericarditis. This safety signal is consistent across multiple COVID-19 vaccine platforms.
Market Competition Challenges: Nuvaxovid has faced significant market challenges competing with established mRNA vaccines from Pfizer-BioNTech and Moderna. The vaccine's later market entry and the dominance of mRNA vaccines created commercial difficulties for Novavax, leading to financial challenges and the need for the Sanofi partnership to ensure continued commercial viability.
Allergic Reaction Concerns: Nuvaxovid carries contraindications for individuals with known severe allergic reactions to any component of the vaccine, including the Matrix-M adjuvant. The saponin-based adjuvant, while effective, presents different allergic reaction profiles compared to mRNA vaccine components, requiring careful screening and management of vaccine recipients.
Nuvaxovid Ownership: Pros & Cons
Advantages
- +Nuvaxovid's protein subunit mechanism, using recombinant nanoparticle technology and the Matrix-M adjuvant rather than mRNA or viral vector technology, provides a traditional vaccine platform that may be preferred by individuals hesitant about mRNA vaccines or who have had adverse reactions to mRNA-based COVID-19 vaccines
- +The PREVENT-19 Phase 3 trial demonstrated 90.4 percent efficacy against symptomatic COVID-19 and 100 percent efficacy against moderate and severe disease, with a favorable safety profile that supports Nuvaxovid's use as an alternative to mRNA vaccines
- +The FDA's full BLA approval of Nuvaxovid on May 19, 2025, converting the vaccine from emergency use authorization to full approval, strengthens the regulatory standing of the vaccine and supports its continued use in annual COVID-19 vaccination programs
- +Novavax's co-commercialization agreement with Sanofi, which provides approximately $1.2 billion in upfront funding and access to Sanofi's global vaccine commercial infrastructure, supports Nuvaxovid's international distribution and reduces Novavax's commercial risk
- +Nuvaxovid's storage requirements (refrigerator temperature, 2 to 8 degrees Celsius) are less demanding than the ultra-cold storage requirements of some mRNA vaccines, potentially simplifying distribution and storage logistics in some settings
Considerations
- -Nuvaxovid's market share in the United States has been limited compared to the Pfizer-BioNTech and Moderna mRNA vaccines, which achieved dominant market positions during the initial COVID-19 vaccination campaigns and have maintained strong brand recognition among healthcare providers and patients
- -Novavax is a relatively small biotechnology company with revenues of approximately $1.0 billion in fiscal year 2024, significantly smaller than the large pharmaceutical companies marketing competing COVID-19 vaccines, which limits its commercial resources and negotiating power with governments and payers
- -The COVID-19 vaccine market has become increasingly competitive and price-sensitive as the acute phase of the pandemic has passed, with governments and payers negotiating lower prices and purchasing fewer doses than during the peak vaccination campaigns
- -Novavax's financial position has been challenging, with the company requiring significant capital raises and the Sanofi partnership to fund its operations, creating uncertainty about its long-term financial sustainability as a standalone company
- -The annual update cycle for COVID-19 vaccines requires Novavax to rapidly develop, manufacture, and seek regulatory authorization for updated formulations each year, creating ongoing operational and regulatory challenges
Frequently Asked Questions About Nuvaxovid
Sources & Further Reading
- Novavax Investor Relations
- Novavax Sustainability & ESG
- FDA Nuvaxovid Approval Announcement
- CDC Clinical Considerations for Myocarditis
- PREVENT-19 Phase 3 Clinical Trial Results — New England Journal of Medicine, 2022
- Novavax Sanofi Partnership Announcement
- Vaccine Adverse Event Reporting System (VAERS)
Where to Buy
Disclosure: We may earn commission from purchases
Nuvaxovid on AmazonCompetitors to Nuvaxovid
No direct competitors found in the same category. This could be because Nuvaxovidoperates in a unique market segment or we're still building our competitor database.
Novavax, Inc. Stock Information
Jobs at Novavax, Inc.
Latest News About Nuvaxovid
Related Articles About Nuvaxovid
View more articles
Monthly IPO Roundup: July 2026 — June's Biggest Listings
June 2026 was the most historic IPO month in market history: SpaceX priced at $135 per share on June 12, raising $75 billion in the largest IPO ever. Quantinuum raised $1.68B, INNIO priced a $2.8B deal, and Bending Spoons filed for a $20B Nasdaq listing. Full recap.
Monthly M&A Roundup: June 2026 Brand Ownership Changes
June 2026's biggest brand ownership moves: Berkshire Hathaway agreed to buy Taylor Morrison for $6.8B, GSK struck a $10.6B deal for Nuvalent, CRH acquired Arcosa for $8.5B, and Qualcomm agreed to buy AI startup Modular for $3.92B. Full breakdown of every major deal.
A Complete Guide to LVMH Brands: What Does the Luxury Giant Own?
LVMH owns 75 luxury maisons including Louis Vuitton, Dior, Tiffany, Guerlain, and Sephora. Here is the complete brand list by division, with acquisition dates and what each brand does.
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Activase
Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.
Acuvue
Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vision Care, a division of Johnson & Johnson. The brand covers daily, weekly, and monthly disposable soft contact lenses sold in more than 100 countries.